Author

Ben Li

Observed name: Li, Ben

Institution: Fosun Pharma (China)

Observed institution: Fosun Pharma (China)

ORCID: 0009-0009-5828-8477

Observed ORCID: 0009-0009-5828-8477

OpenAlex ID: A5136055967

A Phase 2 Study of the MEK1/2 Inhibitor Luvometinib in Patients with Extracranial Arteriovenous Malformations

2026 · Chen Hua, Zhuli Wu, et al. · Clinical Cancer Research · 1

Supplementary Table S3 from A Phase 2 Study of the MEK1/2 Inhibitor Luvometinib in Patients with Extracranial Arteriovenous Malformations

2026 · Chen Hua, Zhuli Wu, et al.

Supplementary Table S6 from A Phase 2 Study of the MEK1/2 Inhibitor Luvometinib in Patients with Extracranial Arteriovenous Malformations

2026 · Chen Hua, Zhuli Wu, et al.

Supplementary Table S1 from A Phase 2 Study of the MEK1/2 Inhibitor Luvometinib in Patients with Extracranial Arteriovenous Malformations

2026 · Chen Hua, Zhuli Wu, et al.

Supplementary Figure S1 from A Phase 2 Study of the MEK1/2 Inhibitor Luvometinib in Patients with Extracranial Arteriovenous Malformations

2026 · Chen Hua, Zhuli Wu, et al.

Data from A Phase 2 Study of the MEK1/2 Inhibitor Luvometinib in Patients with Extracranial Arteriovenous Malformations

2026 · Chen Hua, Zhuli Wu, et al.

Supplementary Table S4 from A Phase 2 Study of the MEK1/2 Inhibitor Luvometinib in Patients with Extracranial Arteriovenous Malformations

2026 · Chen Hua, Zhuli Wu, et al.

Supplementary Figure S2 from A Phase 2 Study of the MEK1/2 Inhibitor Luvometinib in Patients with Extracranial Arteriovenous Malformations

2026 · Chen Hua, Zhuli Wu, et al.

Supplementary Table S2 from A Phase 2 Study of the MEK1/2 Inhibitor Luvometinib in Patients with Extracranial Arteriovenous Malformations

2026 · Chen Hua, Zhuli Wu, et al.

Supplementary Table S5 from A Phase 2 Study of the MEK1/2 Inhibitor Luvometinib in Patients with Extracranial Arteriovenous Malformations

2026 · Chen Hua, Zhuli Wu, et al.

Works count: 12

Citation count: 1

H-index: 1

I10-index: